Brufsky A - Search Results

1

Adjuvant endocrine therapy for premenopausal women with breast cancer.

Puhalla S, Brufsky A, Davidson N. Puhalla S, et al. Among authors: brufsky a. Breast. 2009 Oct;18 Suppl 3(0 3):S122-30. doi: 10.1016/S0960-9776(09)70286-3. Breast. 2009. PMID: 19914530 Free PMC article. Review.

2

Cognitive impairment associated with adjuvant therapy in breast cancer.

Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, Ryan CM. Bender CM, et al. Psychooncology. 2006 May;15(5):422-30. doi: 10.1002/pon.964. Psychooncology. 2006. PMID: 16097037

3

Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.

Brufsky A, Lembersky B, Schiffman K, Lieberman G, Paton VE. Brufsky A, et al. Clin Breast Cancer. 2005 Aug;6(3):247-52. doi: 10.3816/CBC.2005.n.027. Clin Breast Cancer. 2005. PMID: 16137436

4

Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.

Brufsky A. Brufsky A. Semin Oncol. 2006 Apr;33(2 Suppl 7):S13-7. doi: 10.1053/j.seminoncol.2006.03.022. Semin Oncol. 2006. PMID: 16730272 Review.

5

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.

Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA. Brufsky A, et al. J Clin Oncol. 2007 Mar 1;25(7):829-36. doi: 10.1200/JCO.2005.05.3744. Epub 2006 Dec 11. J Clin Oncol. 2007. PMID: 17159193 Clinical Trial.

6

Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.

Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, Cohen SM, Casillo FE, Berga SL. Bender CM, et al. Menopause. 2007 Nov-Dec;14(6):995-8. doi: 10.1097/gme.0b013e318148b28b. Menopause. 2007. PMID: 17898668 Free PMC article.

7

Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.

Brufsky AM. Brufsky AM. Clin Breast Cancer. 2007 Dec;8 Suppl 1:S22-34. doi: 10.3816/cbc.2007.s.009. Clin Breast Cancer. 2007. PMID: 18282367 Review.

8

Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors.

Brufsky AM. Brufsky AM. Curr Oncol Rep. 2008 Jan;10(1):18-26. doi: 10.1007/s11912-008-0005-z. Curr Oncol Rep. 2008. PMID: 18366957 Review.

9

What do perceived cognitive problems reflect?

Bender CM, Pacella ML, Sereika SM, Brufsky AM, Vogel VG, Rastogi P, Casillo FE, Richey SM, Ryan CM. Bender CM, et al. J Support Oncol. 2008 May-Jun;6(5):238-42. J Support Oncol. 2008. PMID: 18551862 Free PMC article.

10

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA. Brufsky AM, et al. Clin Breast Cancer. 2009 May;9(2):77-85. doi: 10.3816/CBC.2009.n.015. Clin Breast Cancer. 2009. PMID: 19433387 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

375 results

Search Page

Filters